Web4 jan. 2024 · Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2024 Results and Corporate Update. January 19, 2024. Editas Medicine and … Web4 mei 2024 · Editas Medicine is developing EDIT-101 for the treatment for Leber Congenital Amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder. Previously …
Did you know?
Web4 aug. 2024 · Editas Medicineannounced the appointment of Chi Li, Ph.D., MBA, RAC, as the Company’s Senior Vice President and Chief Regulatory Officer. Dr. Librings to Editas … Web20 jan. 2024 · The biggest setback was Editas’ announcement in November 2024 that it was pausing development of its lead clinical program EDIT-101, which was being evaluated in the phase 1/2 BRILLIANCE trial (NCT03872479) after disappointing efficacy in treating Leber congenital amaurosis 10. 2 Another trial, the RUBY trial (NCT04853576) of EDIT-301 for …
Web13 apr. 2024 · Exchange Traded Concepts LLC bought a new position in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Rating) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.The fund bought 87,616 shares of the company's stock, valued at approximately $777,000. Web17 nov. 2024 · CAMBRIDGE, Mass., Nov. 17, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced clinical …
Web19 jan. 2024 · Dive Brief: Editas Medicine will sell its cancer cell therapy work to privately held Shoreline Biosciences as part of a company-wide restructuring that’s already led to … Web5 mei 2024 · Editas Medicine Announces First Quarter 2024 Results and Update Strengthening Leadership by Adding Mark S. Shearman, Ph.D., as Chief Scientific Officer Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting
WebCAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a …
Web9 jan. 2024 · CAMBRIDGE, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced a strategic … hoarding in hell 30Web19 jan. 2024 · CAMBRIDGE, Mass. and SAN DIEGO, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it has entered into a definitive agreement with Shoreline Biosciences (Shoreline) for Shoreline to license Editas Medicine’s proprietary SLEEK (SeLection by … hris parallel testing explationWeb22 feb. 2024 · In December 2024, Editas Medicine announced positive safety and efficacy data from the first two patients treated in the RUBY trial, suggesting clinical proof-of … hoarding in hell 29Web8 feb. 2024 · CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy ... hris pdfWeb4 aug. 2024 · Editas had cash, cash equivalents and investments worth $527.6 million as of Jun 30, 2024 compared with $566.4 million as of Mar 31, 2024. Shares of Editas were up 13.4% on Wednesday following the announcement of the earnings result. The stock has plunged 29.6% in the year compared with the industry’s decrease of 22.1%. hris payrollWebEditas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, and precise genomic medicines for a broad class of diseases. Our corporate headquarters is located in Cambridge, MA, and we have a significant and growing site in Boulder, CO. We are pioneering the possibilities of genomic medicines through gene ... hris peoplecoreWeb13 apr. 2024 · CAMBRIDGE, Mass., April 13, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the … hris pbcgov